May 18, 2017. Patients with Duchenne muscular dystrophy and their loved ones deserve the benefits of the most rigorous research available. At the same time, investing in a clinical trial requires significant time and effort, and patients ALWAYS face risks without any guarantee of benefits. Patients and families who are willing to participate in a clinical trial that has the potential to benefit many should be fully informed about the potential risks and benefits of their participation in order to make a decision that is best for them.
Read More »On Medical Treatments & Products
NCHR Testimony at the FDA about a Vaccine for Respiratory Syncytial Virus (RSV)
Megan Polanin May 17 2017: The NCHR advises the FDA to be cautious when approving RSV vaccines, emphasizing the need for strong evidence of safety and effectiveness, especially before giving them to infants who have never had RSV.
Read More »NCHR Comments to FDA Advisory Committee on Organ Care System-Lung
The National Center for Health Research recommends the FDA postpone approval of the Organ Care System (OCS) Lung due to significant flaws in the INSPIRE trial, including design and implementation issues. These compromise the reliability of its findings and pose risks to patient safety.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for Breast Cancer: Medications for Risk Reduction
April 19, 2017. We support the USPSTF’s efforts to re-evaluate recommendations as the scientific evidence expands and improves. In addition, we strongly urge the USPSTF to consider how the apparently modest benefits of medications compare to specific lifestyle changes for reducing breast cancer risk.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
April 12, 2017. We support the USPSTF’s efforts to provide updated recommendations on risk assessment, genetic counseling, and genetic testing on BRCA-related cancer, based on quality, up-to-date scientific studies. We hope the review will quantify the benefits and harms of each step starting with screening, in order to help USPSTF to make meaningful recommendations for appropriate subpopulations of women.
Read More »